ALKBH5 and breast cancer: Thalhammer and colleagues identified that the ALKBH5 promoter contains two putative binding sites for HIF-1α and was up-regulated in response to hypoxia across several different cancer cell lines, including U2OS, breast cancer cell line MCF7, and neuroblastoma cell line IMR32 [32].